<DOC>
	<DOC>NCT00322868</DOC>
	<brief_summary>Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease. Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will be measured in induced sputum specimens before and after a 4 week treatment period with pioglitazone in clinically stable CF patients.</brief_summary>
	<brief_title>Safety and Efficacy of Pioglitazone as an Anti-Inflammatory for the Treatment of CF Lung Disease</brief_title>
	<detailed_description>Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease. Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will be measured in induced sputum specimens before and after a 4 week treatment period with pioglitazone in clinically stable CF patients.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Male or female &gt;= 28 years of age Confirmed diagnosis of cystic fibrosis FEV1 &gt;= 40% predicted Clinically stable Ability to reproduce spirometry Ability to understand and sign the informed consent Use of an investigational agent within 4week period prior to Visit 1 Chronic daily use of ibuprofen or other NSAIDS Chronic daily use of insulin,oral diabetic agents or oral hypoglycemic agents History of hypersensitivity to beta agonists History of hypersensitivity to glitazones Oxygen saturation&lt;92% Pregnant, breastfeeding or unwilling to practice acceptable birth control History of hemoptysis &gt;30cc per episode within 30 days prior to Visit 1 Significant history of hepatic, cardiovascular, renal,neurologic, hematologic or peptic ulcer disease SGOT/SGPT &gt;3 times the upper limit of normal at screening, documented biliary cirrhosis,or portal hypertension Creatinine &gt; 1.8 mg/dL at screening Inability to swallow pills Presence or abnormality that in the opinion of the investigator would compromise the safety or the quality of the data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Prescription drugs</keyword>
	<keyword>Administration, oral</keyword>
	<keyword>Durable medical equipment</keyword>
	<keyword>Kinetics</keyword>
</DOC>